ASCO: GLP-1 receptor agonists may reduce risk for obesity-related cancer, all-cause death

For adults with diabetes and obesity, glucagon-like peptide-1 receptor agonists (GLP-1 RAs) are associated with a reduced risk for obesity-related cancer compared with dipeptidyl peptidase-4 (DPP-4) inhibitors, according to a study scheduled to be presented at the annual meeting of the American Society of Clinical Oncology, held from May 31 to June 4 in Chicago.

This article was originally published on MedicalXpress.com

You may also be interested in:

Read More:

Lawyers Lookup